Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Total Liabilities (2020 - 2026)

Edgewise Therapeutics has reported Total Liabilities over the past 7 years, most recently at $25.3 million for Q1 2026.

  • Quarterly results put Total Liabilities at $25.3 million for Q1 2026, up 2.62% from a year ago — trailing twelve months through Mar 2026 was $25.3 million (up 2.62% YoY), and the annual figure for FY2025 was $30.3 million, up 9.95%.
  • Total Liabilities reached $25.3 million in Q1 2026 per EWTX's latest filing, down from $30.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $30.3 million in Q4 2025 and bottomed at $11.0 million in Q2 2022.
  • Median Total Liabilities over the past 5 years was $21.2 million (2024), compared with a mean of $21.1 million.
  • The largest annual shift saw Total Liabilities soared 155.39% in 2022 before it rose 2.62% in 2026.
  • Over 5 years, Total Liabilities stood at $20.4 million in 2022, then increased by 4.02% to $21.2 million in 2023, then surged by 30.16% to $27.6 million in 2024, then increased by 9.95% to $30.3 million in 2025, then fell by 16.57% to $25.3 million in 2026.
  • Business Quant data shows Total Liabilities for EWTX at $25.3 million in Q1 2026, $30.3 million in Q4 2025, and $24.8 million in Q3 2025.